MicroRNA‑31 is a potential biomarker for screening B‑lymphoblastic leukemia in children

Zhang,Yan; Li,Xin; Bai,Liping; Li,Li; Li,Danhong; Ding,Xue; Wang,Bo; Li,Chengwei

doi:10.3892/ol.2019.10843

MicroRNA‑31 is a potential biomarker for screening B‑lymphoblastic leukemia in children

Authors:
- Yan Zhang
- Xin Li
- Liping Bai
- Li Li
- Danhong Li
- Xue Ding
- Bo Wang
- Chengwei Li
View Affiliations

Affiliations: Department of Hematology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China, Department of Pediatric Medicine, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China, Department of Clinical Laboratory, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China
Published online on: September 10, 2019 https://doi.org/10.3892/ol.2019.10843
Pages: 4930-4935

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression and significance of microRNA‑31 (miR‑31) in children with acute B‑lymphoblastic leukemia (B‑ALL). Bone marrow specimens and peripheral blood were collected from children with B‑ALL (n=38) and healthy controls (n=18). Total RNA was extracted and the expression levels of miR‑31 were measured using quantitative PCR. In addition, a receiver operating characteristic curve was generated, and the area under the curve (AUC) was calculated to evaluate the diagnostic value of miR‑31 for the development of B‑ALL. miR‑31 expression was significantly lower in the B‑ALL group compared with in the control group (P<0.05). Additionally, the expression levels of miR‑31 in the B‑ALL group before treatment were markedly lower than in the B‑ALL group after treatment, and miR‑31 expression was significantly lower after 30 days of treatment compared with after 12 weeks of treatment. Furthermore, miR‑31 expression in the group of children ≥10 years of age was higher than that in the group of children <10 years of age. Furthermore, the expression levels of miR‑31 were higher in the low‑risk group compared with in the medium‑ and high‑risk groups (P<0.05). When the cutoff value was set at 1.8, the AUC of miR‑31 for B‑ALL diagnosis was 0.915 (95% CI, 0.828‑1.000; P<0.0001), with a sensitivity and specificity of 80.8 and 100%, respectively. In conclusion, miR‑31 may exert an anticancer role in B‑ALL in children and may be a potential marker to assist in diagnosis and prognostic prediction.

View Figures

View References

1	Akiyama M, Yamada O, Agawa M, Yuza Y, Yanagisawa T, Eto Y and Yamada H: Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia. J Pediatr Hematol Oncol. 30:313–316. 2008. View Article : Google Scholar : PubMed/NCBI
2	Luan C, Yang Z and Chen B: The functional role of microRNA in acute lymphoblastic leukemia: Relevance for diagnosis, differential diagnosis, prognosis, and therapy. Onco Targets Ther. 8:2903–2914. 2015.PubMed/NCBI
3	Fang M, Becker PS, Linenberger M, Eaton KD, Appelbaum FR, Dreyer Z, Airewele G, Redell M, Lopez-Terrada D, Patel A, et al: Adult low-hypodiploid acute B-Lymphoblastic leukemia with IKZF3 deletion and TP53 mutation: Comparison with pediatric patients. Am J Clin Pathol. 144:263–270. 2015. View Article : Google Scholar : PubMed/NCBI
4	Severson EA, Vergilio JA, Gay LM, Daniel S, Hemmerich AC, Elvin JA, Britt N, Nahas M, Cohen MB, Brown C, et al: Genomic landscape of adult and pediatric BCR-ABL1-like b-lymphoblastic leukemia using parallel DNA and RNA sequencing. Oncologist. 24:372–374. 2019. View Article : Google Scholar : PubMed/NCBI
5	Evensen NA, Madhusoodhan PP, Meyer J, Saliba J, Chowdhury A, Araten DJ, Nersting J, Bhatla T, Vincent TL, Teachey D, et al: MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica. 103:830–839. 2018. View Article : Google Scholar : PubMed/NCBI
6	Oberley MJ, Li S, Orgel E, Phei Wee C, Hagiya A and O'Gorman MRG: Clinical significance of isolated myeloperoxidase expression in pediatric B-Lymphoblastic leukemia. Am J Clin Pathol. 147:374–381. 2017. View Article : Google Scholar : PubMed/NCBI
7	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
8	Crist WM, Furman W and Strother D.and Pui CH: Acute lymphocytic leukemia in childhood: Immunologic marker, cytogenetic, and molecular studies. South Med J. 80:841–847. 1987. View Article : Google Scholar : PubMed/NCBI
9	Subspecialty Group of Hematology and The Society of Pediatrics, Chinese Medical Association, . Summary of the 16th national conference of pediatric hematology. Zhonghua Er Ke Za Zhi (Chinese). 51:76–77. 2013.
10	Douet-Guilbert N, Chauveau A, Gueganic N, Guillerm G, Tous C, Le Bris MJ, Basinko A, Morel F, Ugo V and De Braekeleer M: Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion. Hematol Oncol. 35:385–389. 2017. View Article : Google Scholar : PubMed/NCBI
11	Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, et al: Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. Am J Hematol. 92:344–350. 2017. View Article : Google Scholar : PubMed/NCBI
12	Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM, et al: miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 132:2179–2182. 2018. View Article : Google Scholar : PubMed/NCBI
13	El-Khazragy N, Elshimy AA, Hassan SS, Matbouly S, Safwat G, Zannoun M and Riad RA: Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia. J Cell Biochem. 2–Nov;2018.(Epub ahead of print).
14	Gutierrez-Camino A, Umerez M, Martin-Guerrero I, García de Andoin N, Santos B, Sastre A, Echebarria-Barona A, Astigarraga I, Navajas A and Garcia-Orad A: Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J. 18:704–712. 2018. View Article : Google Scholar : PubMed/NCBI
15	He Z, Liao Z, Chen S, Li B, Yu Z, Luo G, Yang L, Zeng C and Li Y: Downregulated miR-17, miR-29c, miR-92a and miR-214 may be related to BCL11B overexpression in T cell acute lymphoblastic leukemia. Asia Pac J Clin Oncol. 14:e259–e265. 2018. View Article : Google Scholar : PubMed/NCBI
16	Hong Z, Zhang R and Qi H: Diagnostic and prognostic relevance of serum miR-195 in pediatric acute myeloid leukemia. Cancer Biomark. 21:269–275. 2018. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Zou Y, Lin L, Ma X and Chen H: Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia. Cancer Biomark. 22:799–805. 2018. View Article : Google Scholar : PubMed/NCBI
18	Jiang Q, Lu X, Huang P, Gao C, Zhao X, Xing T, Li G, Bao S and Zheng H: Expression of miR-652-3p and effect on apoptosis and drug sensitivity in pediatric acute lymphoblastic leukemia. Biomed Res Int. 2018:57246862018. View Article : Google Scholar : PubMed/NCBI
19	Zang Y, Yu R, Bai Y and Chen X: MicroRNA-9 suppresses cancer proliferation and cell cycle progression in acute lymphoblastic leukemia with inverse association of neuropilin-1. J Cell Biochem. 119:6604–6613. 2018. View Article : Google Scholar : PubMed/NCBI
20	Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron N and Shpilberg O: Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 7:e355012012. View Article : Google Scholar : PubMed/NCBI
21	Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, et al: Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell. 21:121–135. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, Borowitz MJ, Devidas M, Maloney KW, Larsen E, et al: Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 131:1350–1359. 2018. View Article : Google Scholar : PubMed/NCBI
23	Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 111:4477–4489. 2008. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI